Raymond James Raises Amedisys (NASDAQ:AMED) Price Target to $144.00

Share on StockTwits

Amedisys (NASDAQ:AMED) had its price objective hoisted by stock analysts at Raymond James from $140.00 to $144.00 in a note issued to investors on Monday, The Fly reports. The brokerage presently has an “outperform” rating on the health services provider’s stock. Raymond James’ price objective would suggest a potential upside of 16.33% from the company’s previous close.

Several other equities analysts have also recently commented on the stock. Jefferies Financial Group set a $150.00 target price on shares of Amedisys and gave the stock a “buy” rating in a research report on Monday, July 8th. ValuEngine raised shares of Zumiez from a “sell” rating to a “hold” rating in a research report on Saturday, June 22nd. BidaskClub cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 9th. Finally, Barclays set a €77.00 ($89.53) target price on shares of HeidelbergCement and gave the stock a “buy” rating in a research report on Thursday, March 21st. Seven investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $131.74.

Amedisys stock opened at $123.79 on Monday. Amedisys has a 52 week low of $92.08 and a 52 week high of $140.91. The business’s 50 day moving average price is $118.90. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.91 and a current ratio of 0.91. The company has a market cap of $3.98 billion, a PE ratio of 34.10, a P/E/G ratio of 1.53 and a beta of 1.35.

Amedisys (NASDAQ:AMED) last posted its earnings results on Tuesday, April 30th. The health services provider reported $1.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.89 by $0.22. Amedisys had a net margin of 7.14% and a return on equity of 28.25%. The firm had revenue of $467.34 million for the quarter, compared to analysts’ expectations of $460.83 million. During the same quarter last year, the firm earned $0.79 EPS. The company’s quarterly revenue was up 17.0% compared to the same quarter last year. As a group, sell-side analysts expect that Amedisys will post 4.08 EPS for the current fiscal year.

In related news, Director Bruce D. Perkins purchased 2,500 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The stock was bought at an average price of $111.84 per share, for a total transaction of $279,600.00. Following the purchase, the director now directly owns 22,088 shares in the company, valued at approximately $2,470,321.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David L. Kemmerly sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $115.17, for a total transaction of $575,850.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 45,028 shares of company stock valued at $5,210,707. 2.90% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the stock. LPL Financial LLC bought a new position in shares of Amedisys during the 4th quarter worth approximately $300,000. PNC Financial Services Group Inc. lifted its position in shares of Amedisys by 8.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,923 shares of the health services provider’s stock worth $459,000 after buying an additional 322 shares during the period. Raymond James & Associates lifted its position in shares of Amedisys by 82.9% during the 4th quarter. Raymond James & Associates now owns 7,182 shares of the health services provider’s stock worth $841,000 after buying an additional 3,255 shares during the period. Commonwealth Equity Services LLC lifted its position in shares of Amedisys by 2.6% during the 4th quarter. Commonwealth Equity Services LLC now owns 3,704 shares of the health services provider’s stock worth $433,000 after buying an additional 95 shares during the period. Finally, Raymond James Financial Services Advisors Inc. bought a new position in shares of Amedisys during the 4th quarter worth approximately $349,000. Institutional investors and hedge funds own 86.45% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Featured Article: Growth and Income Funds

The Fly

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Millendo Therapeutics  Stock Rating Reaffirmed by Wedbush
Millendo Therapeutics Stock Rating Reaffirmed by Wedbush
Momo  Upgraded to “Sell” at BidaskClub
Momo Upgraded to “Sell” at BidaskClub
Zacks Investment Research Downgrades Motus GI  to Hold
Zacks Investment Research Downgrades Motus GI to Hold
Misonix  Stock Rating Reaffirmed by BTIG Research
Misonix Stock Rating Reaffirmed by BTIG Research
Misonix  Rating Reiterated by Canaccord Genuity
Misonix Rating Reiterated by Canaccord Genuity
BidaskClub Upgrades Kimball International  to Hold
BidaskClub Upgrades Kimball International to Hold


© 2006-2019 Ticker Report